Dr Reddy's To Earmark Rs 1,500 Crore Capex For Biosimilars, Injectables
Sunday, November 6, 2022
Comment
Dr Reddy's Laboratories has earmarked a capex of around Rs 1,500 crore for FY23 with major part of it slated to go into building capacities for its biosimilar and injectable businesses.
from NDTV Profit-Latest https://ift.tt/726GaeF
from NDTV Profit-Latest https://ift.tt/726GaeF
0 Response to "Dr Reddy's To Earmark Rs 1,500 Crore Capex For Biosimilars, Injectables"
Post a Comment